Anti-inflammatory compounds and methods of use

Patent metadata

Field	Value
Publication number	US-2020354417-A1
Application number	US-202016943763-A
Country	US
Kind code	A1
Filing date	Jul 30, 2020
Priority date	May 16, 2014
Publication date	Nov 12, 2020
Grant date	—

Abstract

Methods of treating or inhibiting inflammation in a subject include administering an anti-inflammatory protein to the subject. In some embodiments, the protein has at least 80% sequence identity to the amino acid sequence set forth as SEQ ID NO: 1, SEQ ID NO: 17, or fragments thereof. Isolated polypeptides, nucleic acids, and recombinant vectors including a nucleic acid encoding the anti-inflammatory protein (such as a nucleic acid encoding a protein with at least 80% sequence identity to SEQ ID NO: 1, SEQ ID NO: 17, or fragments thereof) operably linked to a heterologous promoter are also disclosed.

First claim

We claim:

1 . A method of treating sepsis or septic shock in a subject, comprising administering to the subject a polypeptide comprising:
an amino acid sequence having at least 90% sequence identity to the amino acid sequence of SEQ ID NO: 1; an amino acid sequence having at least 90% sequence identity to the amino acid sequence of amino acids 1-185 of SEQ ID NO: 1, amino acids 23-185 of SEQ ID NO: 1, or amino acids 192-313 of SEQ ID NO: 1; an amino acid sequence having at least 90% sequence identity to the amino acid sequence of SEQ ID NO: 11; or an amino acid sequence 130-190 amino acids in length and having at least 90% identity to amino acids 1-188 of SEQ ID NO: 11, amino acids 21-188 of SEQ ID NO: 11, or amino acids 189-330 of SEQ ID NO: 11.

2 . The method of claim 1 , wherein the polypeptide comprises:
an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1; an amino acid sequence having at least 95% sequence identity to the amino acid sequence of amino acids 1-185 of SEQ ID NO: 1, amino acids 23-185 of SEQ ID NO: 1, or amino acids 192-313 of SEQ ID NO: 1; an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 11; or an amino acid sequence 130-190 amino acids in length and having at least 95% identity to amino acids 1-188 of SEQ ID NO: 11, amino acids 21-188 of SEQ ID NO: 11, or amino acids 189-330 of SEQ ID NO: 11.

3 . The method of claim 2 , wherein the polypeptide comprises:
the amino acid sequence of SEQ ID NO: 1; the amino acid sequence of amino acids 1-185 of SEQ ID NO: 1, amino acids 23-185 of SEQ ID NO: 1, or amino acids 192-313 of SEQ ID NO: 1; the amino acid sequence of SEQ ID NO: 11; or an amino acid sequence 130-190 amino acids in length comprising the amino acid sequence of amino acids 1-188 of SEQ ID NO: 11, amino acids 21-188 of SEQ ID NO: 11, or amino acids 189-330 of SEQ ID NO: 11.

4 . The method of claim 3 , wherein the polypeptide consists of:
the amino acid sequence of SEQ ID NO: 1; the amino acid sequence of amino acids 1-185 of SEQ ID NO: 1, amino acids 23-185 of SEQ ID NO: 1, or amino acids 192-313 of SEQ ID NO: 1; the amino acid sequence of SEQ ID NO: 11; or the amino acid sequence of amino acids 1-188 of SEQ ID NO: 11, amino acids 21-188 of SEQ ID NO: 11, or amino acids 189-330 of SEQ ID NO: 11.

5 . The method of claim 1 , wherein the amount of the polypeptide administered to the subject is about 1 mg to about 5 g.

6 . The method of claim 1 , wherein the polypeptide is administered to the subject daily, weekly, or monthly.

7 . The method of claim 1 , further comprising administering one or more of antibiotics, vasopressors, or intravenous fluids to the subject.

8 . A method of treating inflammation in a subject, comprising administering to the subject a polypeptide comprising:
an amino acid sequence having at least 90% sequence identity to the amino acid sequence of SEQ ID NO: 11; or an amino acid sequence 130-190 amino acids in length and having at least 90% identity to amino acids 1-188 of SEQ ID NO: 11, amino acids 21-188 of SEQ ID NO: 11, or amino acids 189-330 of SEQ ID NO: 11.

9 . The method of claim 8 , wherein the polypeptide comprises:
an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 11; or an amino acid sequence 130-190 amino acids in length and having at least 95% identity to amino acids 1-188 of SEQ ID NO: 11, amino acids 21-188 of SEQ ID NO: 11, or amino acids 189-330 of SEQ ID NO: 11.

10 . The method of claim 9 , wherein the polypeptide comprises:
the amino acid sequence of SEQ ID NO: 11; or an amino acid sequence 130-190 amino acids in length comprising the amino acid sequence of amino acids 1-188 of SEQ ID NO: 11, amino acids 21-188 of SEQ ID NO: 11, or amino acids 189-330 of SEQ ID NO: 11.

11 . The method of claim 10 , wherein the polypeptide consists of:
the amino acid sequence of SEQ ID NO: 11; or the amino acid sequence of amino acids 1-188 of SEQ ID NO: 11, amino acids 21-188 of SEQ ID NO: 11, or amino acids 189-330 of SEQ ID NO: 11.

12 . The method of claim 8 , wherein the inflammation in the subject comprises rheumatoid arthritis, osteoarthritis, inflammatory lung disease, inflammatory bowel disease, Hirschsprung's associated enterocolitis, pelvic inflammatory disease, periodontal disease, polymyalgia rheumatica, atherosclerosis, systemic lupus erythematosus, systemic sclerosis, Sjogren's Syndrome, asthma, allergic rhinitis, psoriasis, irritable bowel syndrome, necrotizing enterocolitis, atopy, and/or an increase in cytokine expression.

13 . The method of claim 8 , wherein the amount of the polypeptide administered to the subject is about 1 mg to about 5 g.

14 . The method of claim 8 , wherein the polypeptide is administered to the subject daily, weekly, or monthly.

15 . The method of claim 8 , further comprising administering or more of antibiotics, vasopressors, or intravenous fluids to the subject.

Assignees

• Univ Oregon

Inventors

• Guillemin Karen
• Rolig Annah
• Sweeney Emily

Classifications

• A61P29/00 Primary

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title

• C07K14/4702 Primary

  Regulators; Modulating activity · CPC title

• C12N15/70

  Vectors or expression systems specially adapted for E. coli · CPC title

• C07K4/12

  from animals; from humans · CPC title